Alopecia areata

Last reviewed: 24 Aug 2022
Last updated: 23 Sep 2022
23 Sep 2022

FDA and EMA approve baricitinib to treat severe alopecia areata in adults

Baricitinib, a Janus kinase (JAK) inhibitor, is the first systemic drug to be approved by the US Food and Drug Administration and the European Medicine Agency to treat adults with severe alopecia areata. The approval is based on two randomized, placebo-controlled phase 3 trials, which demonstrated that oral baricitinib increases hair regrowth at 36 weeks, compared with placebo, in people with severe alopecia areata. Adverse effects included acne, elevated levels of creatine kinase and increased levels of low and high density lipoprotein cholesterol.[24]

See Management: emerging

Original source of update

Summary

Definition

History and exam

Key diagnostic factors

  • hair loss
  • nonscarring alopecia
  • exclamation point hairs
  • normal underlying skin in bare areas
  • nail pitting
More key diagnostic factors

Other diagnostic factors

  • autoimmunity
Other diagnostic factors

Risk factors

  • autoimmune disease
  • family history of autoimmune disease
More risk factors

Diagnostic investigations

1st investigations to order

  • clinical diagnosis
  • positive hair pull test
More 1st investigations to order

Investigations to consider

  • skin biopsy
  • trichoscopy
More investigations to consider

Treatment algorithm

ACUTE

limited hair loss (treatment desired)

limited hair loss (no treatment desired)

ONGOING

extensive hair loss (treatment desired)

extensive hair loss (no treatment desired)

Contributors

Authors

Fong Seng Lim, MBBS, MMed (FM), FAMS

Senior Consultant

Department of Family Medicine

National University Health System

Singapore

Disclosures

FSL declares that he has no competing interests.

Miny Samuel, PhD

Assistant Director

Research Support Unit

Yong Loo Lin School of Medicine

National University of Singapore

Singapore

Disclosures

MS declares that she has no competing interests.

Acknowledgements

Dr Fong Seng Lim and Dr Miny Samuel would like to gratefully acknowledge Dr Richard A. Strick, Dr Jack Green, and Dr Paradi Mirmirani, previous contributors to this topic. RAS is an honorary member of the National Alopecia Areata Foundation (NAAF) clinical scientific advisory board. JG is an author of a reference cited in this topic. PM declares that he has no competing interests.

Peer reviewers

Maria Hordinsky, MD

Professor and Chair

Department of Dermatology

University of Minnesota

Minneapolis

MN

Disclosures

MH declares that she has no competing interests.

Ralph M. Trueb, MD

Associate Professor

Department of Dermatology

University Hospital of Zurich

Zurich

Switzerland

Disclosures

RMT is an author of a number of references cited in this topic.

  • Alopecia areata images
  • Differentials

    • Trichotillomania
    • Tinea capitis
    • Telogen effluvium
    More Differentials
  • Guidelines

    • British Association of Dermatologists' guidelines for the management of alopecia areata 2012
    • Alopecia areata investigational assessment guidelines: part II
    More Guidelines
  • Patient leaflets

    Alopecia areata

    More Patient leaflets
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer